Patents by Inventor Michael A. Eldon

Michael A. Eldon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10392131
    Abstract: A tool assembly includes a support frame including support beams and support mounts supporting the support beams. The support frame is rigid and used to transport the tool assembly. A support tool is supported by the support frame and includes a faceplate and a supporting grid structure formed with the faceplate as a monolithic structure defined by a series of AM layers. The faceplate has a supporting surface at a top of the support tool for supporting a working component. The supporting grid structure engages the support beams such that loads are transferred between the support tool and the support frame through the support beams. The support frame maintains dimensional stability of the support tool during transport and when resting within an allowable tolerance of the support tool.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 27, 2019
    Assignee: The Boeing Company
    Inventors: Eric Eldon Deck, Michael Palmore Matlack
  • Publication number: 20190049450
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor, and correlating the level of one or more tumor markers in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Application
    Filed: October 3, 2018
    Publication date: February 14, 2019
    Inventors: Yen Lin Chia, Ute Hoch, Alison Hannah, Michael A. Eldon
  • Patent number: 10132810
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: November 20, 2018
    Assignee: Nektar Therapeutics
    Inventors: Yen Lin Chia, Ute Hoch, Alison Hannah, Michael A. Eldon
  • Publication number: 20180028525
    Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.
    Type: Application
    Filed: October 3, 2017
    Publication date: February 1, 2018
    Inventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
  • Patent number: 9801873
    Abstract: Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: October 31, 2017
    Assignee: Nektar Therapeutics
    Inventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
  • Publication number: 20150359849
    Abstract: The inventions provided herein relate to methods, and compositions for increasing neuronal connectivity, neuronal survival and/or axonal growth of a population of neural cells in vitro, ex vivo or in vivo. For in vivo applications, in some embodiments, the methods and compositions described herein can be used to treat cognitive, motor and/or sensory function impairment and/or neurodegeneration in a subject or particularly a human subject {e.g., a human subject who is diagnosed as having, or having a risk, for a neurodegenerative and/or neurological condition such as Alzheimer's disease). Methods for determining a risk for a neurodegenerative condition or disorder, e.g., Alzheimer's disease, in a subject {e.g., a human subject) are also provided herein.
    Type: Application
    Filed: January 31, 2014
    Publication date: December 17, 2015
    Inventors: Michael Eldon GREENBERG, Bulent ATAMAN
  • Publication number: 20150309032
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 29, 2015
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Yen Lin CHIA, Ute HOCH, Alison HANNAH, Michael A. ELDON
  • Publication number: 20150087668
    Abstract: Among other things, a method of treating a human having brain cancer is, the method comprising administering via a non-continuous dosing regimen to the human having brain cancer, a therapeutically effective amount of a pharmaceutical composition comprising a prodrug or a pharmaceutically acceptable salt thereof, wherein the non-continuous dosing regimen comprises administering the pharmaceutical composition no more frequently than once every seven days for at least two dosings.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 26, 2015
    Applicant: Nektar Therapeutics
    Inventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
  • Publication number: 20140378404
    Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a topoisomerase II-inhibiting amount of a long-acting topoisomerase II inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
    Type: Application
    Filed: October 25, 2012
    Publication date: December 25, 2014
    Applicant: Nektar Therapeutics
    Inventors: Ute Hoch, Michael A. Eldon, Abraham C.F. Leung
  • Patent number: 8906353
    Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: December 9, 2014
    Assignee: Nektar Therapeutics
    Inventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
  • Patent number: 8900555
    Abstract: Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.
    Type: Grant
    Filed: July 27, 2007
    Date of Patent: December 2, 2014
    Assignee: Nektar Therapeutics
    Inventors: Mei-Chang Kuo, Michael Eldon, Yiqiong Yuan
  • Patent number: 8404217
    Abstract: Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.
    Type: Grant
    Filed: July 22, 2005
    Date of Patent: March 26, 2013
    Assignee: Novartis AG
    Inventors: Thomas E. Tarara, Jeffry G. Weers, Michael A. Eldon, Rangachari Narashimhan, Andrew Clark
  • Publication number: 20110269789
    Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.
    Type: Application
    Filed: September 23, 2009
    Publication date: November 3, 2011
    Applicant: Nektar Therapeutics
    Inventors: Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
  • Publication number: 20110160186
    Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.
    Type: Application
    Filed: June 9, 2009
    Publication date: June 30, 2011
    Applicant: Nektar Therapeutics
    Inventors: Michael A. Eldon, C. Simone Jude-Fishburn, Hema Gursahani, Myong Gyong Lee
  • Publication number: 20100055049
    Abstract: Aerosolizable formulations comprising: an insulin derivative having an isoelectric point (pI) ranging from about 6 to about 8; and a pharmaceutically acceptable excipient including a precipitating agent.
    Type: Application
    Filed: July 27, 2007
    Publication date: March 4, 2010
    Inventors: Mei-Chang Kuo, Michael A. Eldon, YiQiong Yuan
  • Patent number: 7326691
    Abstract: A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 ?m to about 1.9 ?m. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 ?m to about 1.9 ?m. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 ?m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.
    Type: Grant
    Filed: June 21, 2005
    Date of Patent: February 5, 2008
    Assignee: Nektar Therapeutics
    Inventors: Sarma Duddu, Srinivas Palakodaty, David Lechuga-Ballesteros, Danforth Miller, Alan R. Kugler, Christopher Frantz, Trixie Tan, Richard Malcolmson, Keith Washco, Theresa Sweeney, Thomas E. Tarara, Sarvajna Dwivedi, Michael A. Eldon
  • Publication number: 20060159625
    Abstract: Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well.
    Type: Application
    Filed: July 22, 2005
    Publication date: July 20, 2006
    Applicant: Nektar Therapeutics
    Inventors: Thomas Tarara, Jeffry Weers, Michael Eldon, Rangachari Narashimhan, Andrew Clark
  • Publication number: 20060160871
    Abstract: One or more embodiments of the invention provide various novel formulations, and tablet dosage forms, comprising losartan that are non-crystalline, stable, and/or otherwise improvements over known losartan formulations. One or more embodiments of the invention further provide methods for preparing the formulation, methods for preparing the tablet dosage form, and to methods of administering the tablet dosage and/or formulation comprising losartan. The losartan-containing formulations may be administered to a user to treat hypertension, and related conditions.
    Type: Application
    Filed: December 6, 2005
    Publication date: July 20, 2006
    Applicant: Nektar Therapeutics
    Inventors: Srinivas Palakodaty, Jiang Zhang, Andreas Kordikowski, Linda Daintree, Sarma Duddu, Alan Kugler, Herm Snyder, David Lechuga-Ballesteros, Nagesh Palepu, Michael Eldon
  • Publication number: 20060025355
    Abstract: A composition includes particles including at least about 95 wt % of amphotericin B, wherein the particles have a mass median diameter ranging from about 1.1 ?m to about 1.9 ?m. Another composition also includes particles including at least about 95 wt % of amphotericin B, wherein at least about 80 wt % of the particles have a geometric diameter ranging from about 1.1 ?m to about 1.9 ?m. Yet another composition includes particles including amphotericin B, wherein the particles have a mass median diameter less than about 1.9 ?m, and wherein the amphotericin B has a crystallinity level of at least about 20%. Unit dosage forms, delivery systems, and methods may involve similar compositions.
    Type: Application
    Filed: June 21, 2005
    Publication date: February 2, 2006
    Applicant: Nektar Therapeutics
    Inventors: Sarma Duddu, Srinivas Palakodaty, David Lechuga-Ballesteros, Danforth Miller, Alan Kugler, Christopher Frantz, Trixie Tan, Richard Malcomson, Keith Washco, Theresa Sweeney, Thomas Tarara, Sarvajna Dwivedi, Michael Eldon
  • Publication number: 20040176391
    Abstract: A method of treating and/or providing prophylaxis against a pulmonary fungal infection comprises delivering an aerosolized pharmaceutical formulation comprising an antifungal agent to the lungs. The method comprises determining the minimum inhibitory concentration of the antifungal agent for inhibiting pulmonary fungal growth. A sufficient amount of the pharmaceutical formulation is administered to maintain for a period of time a target antifungal agent lung concentration that is greater than the determined minimum inhibitory concentration. In one version, the antifungal agent is amphotericin B.
    Type: Application
    Filed: December 31, 2003
    Publication date: September 9, 2004
    Applicant: Nektar Therapeutics
    Inventors: Jeffry G. Weers, Thomas E. Tarara, Michael A. Eldon, Rangachari Narasimhan